Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Couriel DR et al. – Anti–Tumor Necrosis Factor Alpha (TNF–?) therapy with infliximab has shown to be effective for patients with steroid–refractory acute graft–versus–host disease (aGVHD). Patients with newly diagnosed aGVHD derive no benefit from the addition of anti–TNF–alpha therapy with infliximab when compared to corticosteroids alone.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address